Published in Obesity and Diabetes Week, June 27th, 2005
Tercica is developing Increlex (mecasermin [rDNA origin] injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), as a treatment for short stature caused by primary IGF-1 deficiency.
The preliminary injunction seeks to prevent Insmed and its predecessor company, Celtrix, from making, using, offering to sell, or selling SomatoKine; and to compel Insmed to grant Tercica joint...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.